Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pumitamig plus nab-paclitaxel in advanced TNBC
NCT05918133Phase 2Active, not recruiting
- Sponsor
- Biotheus
- Start
- Jul 2022
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pumitamig in triple-negative breast cancer (TNBC), sponsored by Biotheus. Primary endpoints: Objective Response Rate at 2 years and Treatment Related Adverse Events at 30 days. Started Jul 2022; status: active, not recruiting.
02
Drugs
pumitamig
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05918133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918133.